Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 13;3(4):418–435. doi: 10.1038/s43587-023-00379-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a, Study design and sample collection timeline. Volunteer participants received two doses of the inactivated SARS-CoV-2 vaccine (CoronaVac or BBIBP-CorV), and blood samples were collected at indicated timepoints. b, SARS-CoV-2 neutralizing IgG, total IgG and IgM quantification by ELISA. The data are presented for all donors. BS, baseline, before vaccination; D14, 14 days after the first dose; D35, 35 days after the first dose, which is 7 days after the second dose; D78, 78 days after the first injection, which is 50 days after the second dose. c, Comparison of SARS-CoV-2 neutralizing antibody titer between young and old donors across the four timepoints. Young: 18–30-year-old healthy donor; Old: 60–85-year-old healthy donor. Significance was assessed by one-way ANOVA corrected for multiple comparisons using the least significant difference (LSD) method. Colored lines were fitted with cross-timepoint averages from each group with shading representing 95% confidence bands. Data are shown as mean ± s.d. n = 169 (121 young and 48 old) for BS, D14 and D35; n = 93 (45 young and 48 old) for D78. For b and c, each dot represents a single individual. P values were determined by one-way ordinary ANOVA.